Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2017, Vol. 37 Issue (4): 98-103    DOI: 10.13523/j.cb.20170413
    
The Progress in the Study of Vaccine Delivery Technology
WANG Zhi-ming
NCPC New Drug Research and Development Co., Ltd. State Key Laboratory of Antibody Drug Development, Shijiazhuang 050015, Chian
Download: HTML   PDF(418KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  Vaccines remain a cornerstone for the control and prevention of infectious disease in both humans and animals so far. Fundamental to the success of vaccination is the efficient delivery of antigenic cargo needed to elicit robust and proactive levels of immune response. The delivery vector can accentuate, improve, even alter the process of immune response. Such a capability would then offer the potential to optimize vaccination outcomes. The reasonable application of the delivery carrier also can improve the prevention efficiency, simplify the immunization program and so on. Vaccine delivery systems currently used in R & D can generally be categorized into biological (e.g. viral or bacterial) and chemical vectors(e.g. microneedle or liposome). An important consideration in adopting delivery technology is effectively using the capabilities and features of the chosen vector to achieve an ideal effect of vaccination. Now the rapid progress of vaccine delivery technology provides a powerful technical support for the development of modern vaccines.

Key wordsVaccine delivery      Biological vectors      Microneedle      Chemical vectors      Liposome     
Received: 15 November 2016      Published: 25 April 2017
ZTFLH:  R97  
Cite this article:

WANG Zhi-ming. The Progress in the Study of Vaccine Delivery Technology. China Biotechnology, 2017, 37(4): 98-103.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170413     OR     https://manu60.magtech.com.cn/biotech/Y2017/V37/I4/98

[1] Fromen C A, Robbins G R, Shen T W, et al. Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc Natl Acad Sci USA, 2015, 112(2):488-493.
[2] Holgado M P,Falivene J,Maeto C, et al. Deletion of A44L, A46R and C12L vaccinia virus genes from the MVA genome improved the vector immunogenicity by modifying the innate immune response generating enhanced and optimized specific T-cell responses. Viruses,2016, 23,8(5):e139.
[3] Draper S J,Cottingham M G,Gilbert S C. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine,2013, 31(39):4223-4230.
[4] Poulet H, Minke J, Pardo M C, et al. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine, 2007, 25(30):5606-5612.
[5] Henao-Restrepo A M, Longini I M, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet,2015, 386(9996):857-866.
[6] Yang H, Jiao H M. Advances on bacterial ghost as novel vaccine and delivery vector. China Biotechnology, 2014, 34(9):108-112.
[7] Maciag P C, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine:a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine, 2009, 27(30):3975-3983.
[8] Yang Y, Hou J, Lin Z, et al. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol, 2014, 11(2):184-196.
[9] Zhang X, Kong W, Wanda S Y, et al. Generation of influenza virus from avian cells infected by Salmonella carrying the viral genome. Plos One, 2015, 10(3):e0119041.
[10] Wang S, Curtiss R. Development of Streptococcus pneumoniae vaccines using live vectors. Vaccine, 2014, 2(1):49-88.
[11] Shahabi V, Maciag P C, Rivera S, et al. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs, 2010, 1(4):235-239.
[12] Bermudez-Humaran L G, Cortes-Perez N G, Le Loir Y, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol, 2004, 53(Pt 5):427-433.
[13] Adel-Patient K, Ah-Leung S, Creminon C, et al. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy, 2005, 35(4):539-546.
[14] Carroll I M, Andrus J M, Bruno-Barcena J M, et al. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol, 2007, 293(4):729-738.
[15] Braat H, Rottiers P, Hommes D W, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol, 2006, 4(6):754-759.
[16] Perrie Y, Crofts F, Devitt A, et al. Designing liposomal adjuvants for the next generation of vaccines. Adv Drug Deliv Rev,2016, 99(Pt A):85-96.
[17] Chatin B, Mevel M, Devalliere J, et al.Liposome-based formulation for intracellular delivery of functional proteins. Mol Ther Nucleic Acids, 2015, 4(6):e244.
[18] Trimaille T, Verrier B. Micelle-based adjuvants for subunit vaccine delivery. Vaccine, 2015, 3(4):803-813.
[19] Shao S, Geng J, Ah Y H, et al. Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens. Nat Chem, 2015, 7(5):438-446.
[20] Larraeta E, McCrudden M T, Courtenay A J, et al. Microneedles:a new frontier in nanomedicine delivery. Pharm Res, 2016,33(5):1055-1073.
[21] DeMuth P C, Min Y, Huang B, et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater, 2013, 12(4):367-376.
[22] Wang B Z, Gill H S, He C, et al. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J Control Release, 2014, 178(1):1-7.
[1] TANG De-ping, MAO Ai-hong, WANG Fang, ZHANG Hong, WANG Li, LIAO Shi-qi. Targeted Delivery of siRNA Mediated by Aptamer Modified Liposome[J]. China Biotechnology, 2015, 35(1): 54-60.
[2] ZHAO Hai-yang, WANG Ze, HUANG Peng-huang, TIAN Hai-shan, LI Xiao-kun, YANG Shu-lin. rhKGF2-EGFP Fusion Expression and Alcohol Liposome Preparation[J]. China Biotechnology, 2014, 34(10): 22-27.
[3] GUO Chun-fang, ZHANG Yang-de, WANG Ji-wei, PAN Yi-feng, LIAO Ming-mei, WANG Ning. Characterization and the Anti-tumor Effect of Doxorubicin Flexible Liposome in vitro[J]. China Biotechnology, 2013, 33(3): 9-14.